XERS (Xeris Biopharma Holdings) FFO


XERS Xeris Biopharma Holdings Inc XERS
71 GF Score
Price $8.35
GF Value $5.19
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings FFO?

FFO (Funds from operations) only applies to REITs.

XERS
71GF Score
Xeris Biopharma Holdings Inc XERS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of $8.35 is trading 60.9% above its estimated GF Value™ of $5.19. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for XERS:

  • FFO:
  • GF Value™: $5.19 vs. price of $8.35 (60.9% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xeris Biopharma Holdings Business Description

Other Exchanges 0A8E:UK2B30:Germany
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score

Get the complete analysis for XERS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.35
Price
$5.19
GF Value